证券研究报告·北交所公司点评报告·橡胶 利通科技（920225） 2025 业绩快报点评：外部不利因素冲击致短 期业绩承压，新业务布局孕育长期增长潜力 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 485.40 | 483.84 | 464.01 | 512.60 | 602.40 | | 同比（%） | 29.50 | (0.32) | (4.10) | 10.47 | 17.52 | | 归母净利润（百万元） | 133.71 | 107.21 | 82.43 | 93.45 | 114.88 | | 同比（%） | 60.78 | (19.82) | (23.12) | 13.38 | 22.93 | | EPS-最新摊薄（元/股） | 1.05 | 0.84 | 0.65 | 0.74 | 0.91 | | P/E（现价&最新摊薄） | 29.80 | 37.17 | 48.35 | 42.64 | 3 ...

智通财经APP获悉，招商证券发布研报称，给予IFBH(06603)"增持"评级，考虑到行业处于成长期+业绩 修复弹性大。公司25年收入/经调整归母净利润分别同比+11.9%/-22.0%，其中25H2收入/经调整净利润 同比-4.5%/-55.1%，收入受innococo大幅下滑影响，利润端则受汇率影响毛利率、营销及上市费用支出 增加拖累。 招商证券主要观点如下： 椰子水行业当前正处于风口期 IF主品牌延续增长，innococo运营调整阶段性下滑，海外市场高增 1)分品牌看：25年IF主品牌收入1.67亿美元，同比+26.9%;Innococo收入0.10亿美元，同比-63.2%，25H2 看，IF主品牌收入0.83亿美元，同比+14.5%，增速放缓主要系下半年部分备货在6月体现导致，innococo 品牌受渠道大商内部管理问题影响，6月开始中断发货，12月才有所恢复，导致H2同比大幅下滑。2)分 区域看：25年中国内地收入1.59亿美元，同比+9.4%，中国香港+中国台湾地区收入0.12亿美元，同比 +40%，海外地区收入0.05亿美元，同比+47.3%，其中澳大利亚、菲律宾及老挝等市场均实现翻倍以上 增长 ...

当前，公司所处行业竞争态势持续加剧，市场价格压力逐步传导至公司各主要业务板块，导致报告期内 公司整体毛利率出现下滑态势。在此背景下，公司三大业务虽保持正常稳健经营，但盈利空间均受到不 同程度挤压，进而影响了报告期内的净利润表现。其中，中低压成套设备业务因本期暂无同期大规模项 目执行，未能形成相应的项目规模效应，该业务单产品毛利同比下降幅度较为显著。整体来看，公司全 年业绩虽受上述因素影响有所下滑，但公司积极应对市场变化，四季度经营态势已出现积极改善，业绩 较前三季度实现转好，经营基本面呈现逐步修复的良好趋势。 威腾电气(688226.SH)披露2025年度业绩快报，2025年度公司实现营业总收入38.48亿元，同比增加 10.55%;归属于母公司所有者的净利润3179.96万元，同比下降66.48%。 ...

Core Viewpoint - The recent share reduction by executives of Meihao Medical (301363) is minimal and will not significantly impact the company's control or governance structure [1][2]. Group 1: Share Reduction Details - On February 11, 2026, certain executives, including Vice Presidents and a board member, reduced their holdings by a total of 54,264 shares, representing 0.0095% of the total share capital [1]. - The reason for the reduction was personal financial needs, and all unrestricted shares have been fully sold, while restricted shares remain [1]. Group 2: Impact of the Share Reduction - The scale of the reduction is very small (less than 0.01%), and the individuals involved are not controlling shareholders, thus there is no significant impact on share concentration or company control [2]. - The company's governance structure remains stable and compliant with legal requirements [2]. Group 3: Stock Performance - Following the announcement of the share reduction on February 12, 2026, the stock closed at 32.73 yuan, up 2.35%, and further increased to 34.81 yuan on February 13, 2026, reflecting a 6.36% rise, indicating limited market reaction [3]. - Recent fluctuations in major fund flows were noted, with a net outflow of 30.29 million yuan on February 6 and a net inflow of 4.02 million yuan on February 12, but the reduction event did not trigger sustained selling pressure [3]. Group 4: Company Fundamentals - For the first three quarters of 2025, the net profit attributable to the parent company decreased by 19.25%, although there was a 5.89% increase in net profit in the third quarter, indicating some recovery in profitability [4]. - The share reduction occurred during a transitional period for performance, which may heighten investor concerns about profit pressures, but new business initiatives (such as weight loss pens and brain-machine interfaces) offer long-term growth potential [4]. - The company has a high customer concentration (with a single client historically accounting for over 60%) and an overseas revenue share of 86.64%, necessitating attention to order stability and exchange rate risks [4].

经济观察网登士柏西诺德(NASDAQ:XRAY)近7天股价出现显著波动。根据实时行情数据，2月12日股价 单日下跌6.78%，收盘报12.78美元，振幅达7.15%。同期，2月10日股价上涨1.68%至13.93美元，但2月 11日回落1.58%至13.71美元。整体区间累计跌幅7.12%，振幅10.25%，最低下探12.77美元。股价异动可 能与市场对牙科行业复苏预期的情绪变化相关，同时医疗设备板块同期下跌3.59%。 机构观点 以上内容基于公开资料整理，不构成投资建议。 机构对登士柏的关注度较高，但近期评级偏谨慎。截至2026年2月，18家机构中仅11%给予买入或增持 观点，83%持有观点，6%建议减持或卖出。目标价区间为11.00-16.00美元，均价12.75美元，接近当前 股价。盈利预测显示，2025年第四季度每股收益预期同比下滑32.79%，营收预期同比微增0.73%。机构 普遍关注公司盈利能力改善进展，尤其在核心市场美国销售额承压的背景下。 近期事件 近期无重大公司事件公告，但市场聚焦于业绩修复前景。登士柏预计在2026年第一季度公布2025年全年 财报，管理层可能更新"重返增长"战略细节。行业 ...

经济观察网 近期，严牌股份（301081）（301081.SZ）股价表现活跃。根据2026年2月12日收盘数据， 公司股价当日上涨6.55%，报收14.16元，成交额1.73亿元，换手率达5.70%。近一个月（2026年1月13日 至2月12日）股价累计上涨33.71%，振幅达38.05%，表现显著强于大盘及行业指数。 股价异动原因 格隆汇2026年1月29日的业绩预告显示，公司预计2025年净利润同比下降55.19%–69.18%，主要因新产 能投放导致短期费用前置及海外关税成本上升。市场关注点在于2026年产能利用率提升带来的利润修复 潜力，部分资金可能提前布局业绩拐点。2月4日公司公告决定不提前赎回"严牌转债"，且未来3个月内 均不行使赎回权。该决议缓解了转债抛压对正股的冲击，当日严牌转债上涨10%，间接提振正股情绪。 资金面与技术面 2月10日至12日主力资金呈现大额净流入（2月12日净流入1006万元），换手率显著放大至5%以上，技 术指标显示KDJ值进入超买区间（J值95.23），短期交易活跃度骤增可能加剧股价波动。 行业政策现状 公司作为工业过滤材料细分领域企业，业务涉及环保减排需求。随着全球对 ...

Core Viewpoint - The company forecasts a significant decline in net profit for 2025, with expected net profit attributable to shareholders ranging from 1.005 to 1.254 billion yuan, representing a year-on-year decrease of 69% to 75% [1] Group 1: Financial Performance - The company's net profit for 2025 is projected to be between 1.005 and 1.254 billion yuan, with a non-recurring net profit of 154 to 231 million yuan, reflecting a year-on-year decline of 91% to 94% [1] - The decline in net profit is attributed to impairment provisions for real estate projects, reduced delivery scale of projects, and decreased investment income from joint ventures [2] - The company expects continued pressure on revenue performance in the short to medium term, with gross margins at a low point [2] Group 2: Sales and Market Position - The company achieved sales of 196 billion yuan in 2025, a decrease of 10.6%, but improved its ranking to 4th in the industry [3] - The average selling price increased by 16.8% to 27,371 yuan per square meter, while land acquisition amounted to 93.8 billion yuan, up 92.8% [3] - The land acquisition intensity improved significantly to 48%, with 89% of land purchases concentrated in core first and second-tier cities [3] Group 3: Financial Health and Strategy - The company maintains a low leverage level, with a debt-to-asset ratio of 61.0% and a net debt ratio of 55.3% as of Q3 2025 [3] - The average financing cost was 2.84%, the lowest in the industry, indicating a strong credit position [3] - The company plans to issue up to 78.405 billion yuan in preferred shares to optimize its balance sheet, with funds allocated to 11 real estate projects in major cities [4] Group 4: Future Outlook - The company anticipates a gradual recovery in performance if the market conditions improve, with projected net profits of 1.06 billion, 1.29 billion, and 1.93 billion yuan for 2025-2027 [4] - The potential for valuation recovery is significant if the industry experiences a turnaround, despite current high apparent PE ratios due to impairment pressures [4]

Core Viewpoint - The company is currently experiencing limited impact from price fluctuations in storage products due to their small proportion in overall business, while it is cautiously monitoring market dynamics for future pricing strategies [1] Group 1: Storage Products - The company’s storage business is in a small batch order phase, including products like NAND flash and eMMC, with ongoing validation and market promotion efforts [1] - Price adjustments for storage products will be made cautiously, considering supply-demand changes and cost factors [1] Group 2: Industry Outlook - The high-reliability electronic components industry is expected to see a recovery in demand starting from Q3 2025, as indicated by feedback from other companies in the sector [1] - Despite a 29.72% year-on-year revenue growth in a single quarter since Q3 2025, the company’s overall annual performance recovery will require more time [1] Group 3: Product Development - The company is facing challenges due to differences in product structure, customer order rhythms, and new product launch progress compared to peers [1] - New products such as radiation-hardened devices and RISC-V MCUs have entered commercial aerospace fields, but significant contributions to scale are still pending [1] - The company is increasing R&D investment and optimizing product structure to address these challenges [1]

Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. has reported a significant improvement in its 2025 performance, with a projected net profit of 100 million to 120 million yuan, representing a year-on-year increase of 192.06% to 250.47% [1][5] Group 1: Financial Performance - The company expects basic earnings per share to be between 0.13 yuan and 0.16 yuan, a notable increase from 0.05 yuan in the previous year [1][5] - The overall operational situation of the company is improving, with key performance indicators showing a steady recovery [1][5] - The performance forecast reflects the company's operational quality and the broader trend of "value reconstruction and strong players breaking through" in the pharmaceutical industry [1][5] Group 2: Strategic Transformation - Yatai Pharmaceutical has successfully transitioned from a phase of operational volatility to a phase of stable recovery, achieving profitability in 2024 and demonstrating strong operational resilience [2][6] - The company has focused on optimizing its product pipeline and divesting non-core businesses, concentrating on antibiotics and antiviral drugs to enhance core business concentration [2][6] - This transformation is indicative of the effectiveness of the company's operational strategies and marks its entry into a high-quality development track [2][6] Group 3: Change in Control - On January 8, 2026, Yatai Pharmaceutical announced the completion of the share transfer process, with Xinghao Holdings becoming the controlling shareholder and Qiu Zhongxun as the new actual controller [3][7] - The change in control is seen as a deep integration of industrial resources and a comprehensive upgrade of development strategies, establishing a framework of "industry + capital + innovation" [3][7] - The collaboration between Yatai Pharmaceutical and Yaodou Technology is expected to activate growth potential across the entire value chain, from research and development to production and distribution [3][7] Group 4: Future Outlook - The company is expected to continue releasing value potential through ongoing industrial collaboration, gradual implementation of innovation pipelines, and sustained improvement in profitability [4][8] - Yatai Pharmaceutical is positioned to contribute to the innovative development of the pharmaceutical industry while achieving its own high-quality growth [4][8]

Group 1 - The report indicates that the recent market downturn was primarily caused by significant fluctuations in gold and silver prices, with the A-share market showing no clear deterioration in trading sentiment [1][9] - Historical data suggests that the average duration of spring market rallies is 39 trading days, with a maximum increase of 15.8%, while the current rally has lasted 31 days with a 9.8% increase, indicating potential for further upward movement [1][9] - The report categorizes the triggers for the end of spring market rallies since 2010, noting that significant pullbacks often occur when domestic fundamentals decline alongside tightening overseas liquidity or geopolitical shocks [2][13] Group 2 - Evidence of performance recovery for listed companies in 2025-2026 is becoming increasingly clear, with a projected 5.3% year-on-year growth in net profit for the first three quarters of 2025 [3][15] - The report highlights that the proportion of companies with upward revisions to earnings expectations for 2026 has risen from 65% to 100% since late November 2025, reflecting optimism about corporate profit recovery [3][15] - Industrial profits are expected to show a positive year-on-year growth of 0.6% in 2025, marking the first positive growth since 2022, with stable profit margins being a key support factor [3][15] Group 3 - The report suggests a shift in the funding landscape, with a transition from short-term speculative capital to long-term household deposits, as a significant amount of household savings is set to mature in 2026 [4][21] - There has been a notable outflow of approximately 1 trillion yuan from broad-based ETFs since the beginning of the year, indicating a cooling of short-term speculative money [4][21] - The issuance of public funds has shown a significant recovery, with new public equity products increasing from 22.1 billion yuan in May 2025 to 69.6 billion yuan by January 2026 [4][21] Group 4 - The report emphasizes a focus on sectors with strong earnings growth expectations, particularly cyclical industries, non-bank financials, and technology sectors with solid fundamentals [5][28] - Specific sectors highlighted include non-bank financials, which have seen a 550% increase in the proportion of companies with upward earnings revisions, and cyclical industries such as metals and construction materials, which are expected to benefit from fiscal stimulus and demand-side incentives [5][28] - The report identifies key themes in technology, such as satellite navigation and commercial aerospace, which are projected to have significant earnings growth in 2026 [5][28]